183 related articles for article (PubMed ID: 1665321)
1. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
Greenberg PD; Reusser P; Goodrich JM; Riddell SR
Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
Riddell SR; Reusser P; Greenberg PD
Rev Infect Dis; 1991; 13 Suppl 11():S966-73. PubMed ID: 1664137
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
4. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
Reusser P; Riddell SR; Meyers JD; Greenberg PD
Blood; 1991 Sep; 78(5):1373-80. PubMed ID: 1652311
[TBL] [Abstract][Full Text] [Related]
6. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
[TBL] [Abstract][Full Text] [Related]
7. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
[TBL] [Abstract][Full Text] [Related]
9. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.
Riddell SR; Walter BA; Gilbert MJ; Greenberg PD
Bone Marrow Transplant; 1994; 14 Suppl 4():S78-84. PubMed ID: 7728132
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
[TBL] [Abstract][Full Text] [Related]
11. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
[TBL] [Abstract][Full Text] [Related]
12. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
[TBL] [Abstract][Full Text] [Related]
13. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus.
Gilbert MJ; Riddell SR; Li CR; Greenberg PD
J Virol; 1993 Jun; 67(6):3461-9. PubMed ID: 8388509
[TBL] [Abstract][Full Text] [Related]
14. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
16. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
[TBL] [Abstract][Full Text] [Related]
17. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation.
Boland GJ; Vlieger AM; Ververs C; De Gast GC
Clin Exp Immunol; 1992 Jun; 88(3):506-11. PubMed ID: 1318805
[TBL] [Abstract][Full Text] [Related]
18. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
19. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.
Woo PC; Lo CY; Lo SK; Siau H; Peiris JS; Wong SS; Luk WK; Chan TM; Lim WW; Yuen KY
Clin Diagn Lab Immunol; 1997 Sep; 4(5):515-8. PubMed ID: 9302197
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
